CascadeDiagnose Prostate MRI

Condition(s) studied

Study summary

This multicenter clinical study is evaluating CascadeDiagnose Prostate MRI, an artificial-intelligence software tool that analyzes standard prostate MRI scans-T2-weighted, diffusion-weighted, and ADC images-to help radiologists detect suspicious prostate lesions, estimate cancer risk, and distinguish prostate cancer from benign conditions. The study will take place at six hospitals in Guangxi and plans to enroll at least 2,000 eligible men aged 18 or older who have had prostate MRI and have confirmed pathology results. It includes a retrospective phase using existing records and a prospective phase in which participants provide written informed consent. The main goals are to measure the system's diagnostic accuracy (AUC, sensitivity, and specificity), compare it with readings by radiologists, assess safety and rates of rejected or indeterminate results, and see whether it improves reading efficiency or helps reduce unnecessary biopsies. To protect patient privacy, raw MRI, medical-record, and pathology data remain inside each hospital; only de-identified, encrypted intermediate results are shared through a secure distributed network. The study requires ethics approval and trial registration before enrollment, and its results may help determine whether this AI tool is safe and effective for clinical use.

Eligibility

Primary outcome measure(s)

• Adverse Events — up to 24 weeks
  All adverse events associated with system usage are documented
• Area under the receiver operating characteristic curve (AUC) — up to 24 weeks
  overall diagnostic performance for discriminating prostate cancer from benign lesions

Trial sites (6)

More First Affiliated Hospital of Guangxi Medical University trials in China

Other trials for the same condition